PT  - JOURNAL ARTICLE
AU  - Mouhand F.H. Mohamed
AU  - Shaikha D. Al-Shokri
AU  - Khaled M. Shunnar
AU  - Sara F. Mohamed
AU  - Mostafa S. Najim
AU  - Shahd I. Ibrahim
AU  - Hazem Elewa
AU  - Khalid M. Dousa
AU  - Lina O. Abdalla
AU  - Ahmed El-Bardissy
AU  - Mohamed Nabil Elshafei
AU  - Ibrahim Y. Abubeker
AU  - Mohammed Danjuma
AU  - Mohamed A Yassin
TI  - Prevalence of Venous Thromboembolism in Critically-ill COVID-19 Patients: Systematic Review and Meta-analysis
AID  - 10.1101/2020.08.24.20175745
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.24.20175745
4099  - http://medrxiv.org/content/early/2020/08/29/2020.08.24.20175745.short
4100  - http://medrxiv.org/content/early/2020/08/29/2020.08.24.20175745.full
AB  - Background Recent studies revealed a high prevalence of venous thromboembolism (VTE) events in coronavirus disease 2019 (COVID-19) patients, especially in those who are critically ill. Available studies report varying prevalence rates. Hence, the exact prevalence remains uncertain. Moreover, there is an ongoing debate regarding the appropriate dosage of thromboprophylaxis. Methods: We performed a systematic review and proportion meta-analysis following PRISMA guidelines. We searched PubMed and EMBASE for studies exploring the prevalence of VTE in critically ill COVID-19 patients till 22/07/2020. We pooled the proportion of VTE. Additionally, in a subgroup analysis, we pooled VTE events detected by systematic screening. Finally, we compared the odds of VTE in patients on prophylactic compared to therapeutic anticoagulation. Results: The review comprised of 24 studies and over 2500 patients. The pooled proportion of VTE prevalence was 0.31 (95% CI 0.24, 0.39 I2 94%), of VTE utilizing systematic screening was 0.48 (95% CI 0.33, 0.63 I2 91%), of deep-venous-thrombosis was 0.23 (95% CI 0.14, 0.32 I2 96%), of pulmonary embolism was 0.14 (95% CI 0.09, 0.20 I2 90%). In a subgroup of studies, utilizing systematic screening, VTE risk increased significantly with prophylactic, compared to therapeutic anticoagulation (OR 5.45; 95% CI 1.90, 15.57 I2 0%). Discussion: Our review revealed a high prevalence of VTE in critically ill COVID-19 patients. Almost 50% of patients had VTE detected by systematic screening. Higher thromboprophylaxis dosages seem to reduce VTE burden in this patient’s cohort compared to standard prophylactic anticoagulation; ongoing randomized controlled trials will further confirm this.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialCRD42020185916Funding StatementNo funding sourceAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Formal ethical approval was not needed for our review since it is a synthesis of already available data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon request from the corresponding author.